Reviva Pharmaceuticals Holdings (RVPH) just unveiled an announcement.
Reviva Pharmaceuticals Holdings, Inc. has provided an update on the progress of their RECOVER trial, which is assessing the safety and efficacy of brilaroxazine for treating schizophrenia. The trial is advancing as planned across the USA, Europe, and Asia with 358 patients enrolled, 223 currently receiving treatment. Notably, 23 patients have completed a full year of treatment, which is crucial as data from 100 such patients is needed for the New Drug Application to the FDA. Reviva anticipates wrapping up this year-long safety study by the fourth quarter of 2024.
See more insights into RVPH stock on TipRanks’ Stock Analysis page.
